The Indian Patent Office often raises morality objections to sexual inventions, particularly in the context of devices and aids. This post analyses such objections, the legal framework under Section 3(b), and the shift towards constitutional morality post the Supreme Court’s 377 judgment. It highlights the need for consistent and rights-based evaluation in patentability decisions.
Read more about Morality and Patentability of Sexual InventionsTag: Patentability
Patentability and Section 3(d), History of Patent Law in India, Patentability of Imatinib Masylate in Beta Crystalline Form – Novartis Case Abridged by Dr. Kalyan C. Kankanala
This abridged Novartis case by Dr. Kalyan C. Kankanala explains the patentability requirements under Section 3(d) of Indian patent law. It provides a structured analysis of the legal and practical issues surrounding the Imatinib Mesylate patent application.
Read more about Patentability and Section 3(d), History of Patent Law in India, Patentability of Imatinib Masylate in Beta Crystalline Form – Novartis Case Abridged by Dr. Kalyan C. KankanalaAnalyzing Patentability of Inventions – A Presentation by Dr. Kalyan C. Kankanala at the UPES School of Law
This presentation is part of the 'Patent Law and Practice Program' being taught by BananaIP Team at UPES School of Law to B.tech-LLB Students. This...
Read more about Analyzing Patentability of Inventions – A Presentation by Dr. Kalyan C. Kankanala at the UPES School of LawPatents, Inventions, Inventors – Who really won the race? A peek into the Strategic Inventor Seminar by BananaIP Counsels
The Strategic Inventor Seminar by BananaIP Counsels provided corporate inventors with practical insights into patentability and infringement risks. Interactive sessions and expert guidance made it a valuable platform for knowledge sharing and networking.
Read more about Patents, Inventions, Inventors – Who really won the race? A peek into the Strategic Inventor Seminar by BananaIP CounselsCan You Invent for Patents? – BananaIP’s Inventor Program Highlights
BananaIP’s inventor program, led by Dr Kalyan Kankanala, focused on practical aspects of patentability and invention assessment. Participants engaged in interactive exercises and gained valuable insights into patent law and documentation.
Read more about Can You Invent for Patents? – BananaIP’s Inventor Program HighlightsPatents and Cow Slaughter
This article examines cow slaughter within the framework of Indian patent law, addressing moral and legal issues surrounding patentability. It discusses relevant patent applications and the influence of shifting public attitudes and legal standards on inventions related to animal slaughter.
Read more about Patents and Cow SlaughterIndian Patent Cases, Patentability Requirements, Patent Litigation, Interesting patents, Patent Licensing, Patent Tips and more
This post provides an analytical overview of Indian patent cases, patentability standards, and litigation trends, supported by detailed statistics and key court decisions. It also examines patent licensing practices and offers practical tips for developing a strong patent portfolio.
Read more about Indian Patent Cases, Patentability Requirements, Patent Litigation, Interesting patents, Patent Licensing, Patent Tips and morePharma Patents and Drug Prices- A Presentation by Dr. Kalyan C. Kankanala at NLSIU, Bangalore
The following presentation titled ‘Pharma Patents and Drug Prices’ was delivered by Dr. Kalyan C. Kankanala (Managing Partner, BananaIP Counsels, Bangalore) on 5th January, 2016...
Read more about Pharma Patents and Drug Prices- A Presentation by Dr. Kalyan C. Kankanala at NLSIU, BangalorePfizer files for Patent on Known Substance
This post examines Pfizer’s patent application on a known substance and the Indian Patent Office’s refusal in light of Section 3d and the Novartis decision. It discusses whether unpublished patent applications can render a substance as “known” and critiques the merging of novelty and subject matter analysis.
Read more about Pfizer files for Patent on Known SubstancePfizer falls prey to Section 3(d)
This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence of enhanced efficacy in pharmaceutical patent applications.
Read more about Pfizer falls prey to Section 3(d)